Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Univercells Technologies develops and commercializes innovative biomanufacturing technologies—most notably the scale-X™ single-use fixed-bed bioreactor and NevoLine™ automated upstream platform—to enable cost-effective production of viral vectors and vaccines from R&D through commercial scales. Their solutions are widely adopted in cell & gene therapy as well as vaccine manufacturing. The company was acquired by Donaldson Company in June 2023 to expand Donaldson’s life sciences portfolio.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Univercells Technologies.